View Older Stories

Feb 25, 2026 04:04PM Revolution Medicines, Inc. (RVMD) Misses Q4 EPS by 28c

Feb 9, 2026 03:45PM Revolution Medicines (RVMD) spreader of April 80, June 50 and June 80 puts

Jan 27, 2026 05:56AM Revolution (RVMD) PT Raised to $150 at Oppenheimer

Jan 26, 2026 08:59AM Truist Securities keeps Revolution (RVMD) at Buy, 'believe that RVMD is well funded and doesn't need to do a deal'

Jan 26, 2026 08:43AM Revolution Medicines stock falls after Merck reportedly ends acquisition pursuit

Jan 25, 2026 02:35PM Merck ends acquisition talks with Revolution Medicines - WSJ

Jan 22, 2026 08:32AM Revolution (RVMD) PT Raised to $170 at Stifel as Pipeline Has Unrecognized Value

Jan 21, 2026 09:06AM Revolution (RVMD) PT Raised to $140 at RBC Capital

Jan 20, 2026 06:54AM Revolution (RVMD) PT Raised to $160 at Guggenheim

Jan 13, 2026 09:07AM Goldman Sachs on Revolution (RVMD): 'Catalyst-rich 2026 underpins the breadth of the clinical portfolio'

Jan 12, 2026 03:23PM RStifel on evolution Medicines (RVMD): 'RVMD's Hand is Looking Stronger Than Ever!'

Jan 12, 2026 09:34AM Truist Securities Reiterates Buy Rating on Revolution (RVMD)

Jan 9, 2026 03:55PM STAT reported Feuerstein: meeting with Revolution Medicines CEO cancelled

Jan 9, 2026 03:02PM Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

Jan 9, 2026 02:44PM Revolution Medicines (RVMD) CEO Said to Cancel Upcoming Meetings Amid M&A Chatter

Jan 9, 2026 04:57AM Revolution (RVMD) PT Raised to $109 at BofA Securities

Jan 8, 2026 04:46PM After-hours movers: Rocket Companies, General Motors, Intel, and more

Jan 8, 2026 04:34PM Merck Discussed $28B-$32B Price For Revolution Medicines - FT

Jan 8, 2026 03:44PM Merck (MRK) in Talks to buy Revolution Medicines (RVMD) - FT

Jan 8, 2026 08:01AM Stifel Reiterates Buy Rating on Revolution (RVMD): Will Remain Independent

Jan 7, 2026 09:00PM BofA top picks in biotech as sector heading for recovery in 2026

Jan 7, 2026 04:59PM After-hours movers: Lockheed Martin, Canadian Solar, Revolution Medicines and more

Jan 7, 2026 04:14PM Abbvie: Not In Discussions With Revolution Medicines - Reuters

Jan 7, 2026 02:50PM AbbVie in Advanced Talks to Buy Revolution Medicines - WSJ

Jan 7, 2026 02:50PM Revolution Medicines (RVMD) halted on circuit breaker following takeover report

Jan 7, 2026 12:28PM Oppenheimer on BridgeBio Oncology Therapeutics, In (BBOT): 'We think the lack of idiosyncratic toxicity is particularly notable for BBO-10203'

Jan 7, 2026 12:11PM Erasca, Inc (ERAS) Pulls Back from 20+pct Jump, Stifel: 'Today's Strength Driven by Competitor Readthrough'

Dec 21, 2025 08:00PM Here's the list of top biotech stocks to own for 2026

Dec 3, 2025 08:21AM TD Cowen: 'Revolution (RVMD) Is Our 2026 Best Idea'

Nov 9, 2025 04:00AM These stocks are latest additions to Mizuho's Top Picks list

Nov 5, 2025 04:08PM Revolution Medicines, Inc. (RVMD) Misses Q3 EPS by 20c

Nov 3, 2025 02:16AM RBC Capital Starts Revolution (RVMD) at Outperform

Oct 27, 2025 08:01AM Revolution Medicines receives FDA orphan drug status for pancreatic cancer drug

Oct 22, 2025 12:13PM Revolution Medicines reports elironrasib data for lung cancer patients

Oct 20, 2025 04:05PM Mizuho Starts Revolution (RVMD) at Outperform

Oct 17, 2025 05:51AM Revolution (RVMD) PT Raised to $80 at BofA Securities

Oct 17, 2025 05:16AM Revolution (RVMD) PT Raised to $76 at Raymond James

Oct 15, 2025 04:09PM Stifel Starts Revolution (RVMD) at Buy

Sep 12, 2025 06:26AM Raymond James Assumes Revolution (RVMD) at Strong Buy, 'a prime takeout target'

Sep 11, 2025 07:07AM Revolution (RVMD) PT Raised to $66 at Needham

Sep 5, 2025 06:03AM Truist Securities Starts Revolution (RVMD) at Buy, PT $99

Aug 25, 2025 05:45AM Oppenheimer Reiterates Outperform Rating on Revolution (RVMD)

Aug 19, 2025 06:17AM Piper Sandler Starts Revolution (RVMD) at Overweight

Aug 18, 2025 07:54AM LifeSci Capital Starts Revolution (RVMD) at Outperform

Aug 6, 2025 05:00PM Revolution Medicines, Inc. (RVMD) Misses Q2 EPS by 19c

Jul 24, 2025 04:00PM Revolution Medicines publishes research on RAS G12D inhibitor in Science

Jul 15, 2025 03:31AM Goldman Sachs Starts Revolution (RVMD) at Buy

Jul 9, 2025 08:01AM Revolution Medicines partners with Iambic for AI drug discovery

Jul 1, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Revolution (RVMD)

Jun 30, 2025 08:07AM Revolution Medicines (RVMD) and Summit Therapeutics (SMMT) Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

View Older Stories